美國(guó)紐約大學(xué)(New York University)的研究報(bào)告稱,白宮為快速篩查感染者所采用的雅培公司(Abbott Laboratories)的新冠病毒檢測(cè),可能漏診了近一半的陽(yáng)性病例,但雅培公司對(duì)這項(xiàng)研究結(jié)果表示質(zhì)疑。
研究人員將雅培的ID NOW檢測(cè)裝置的結(jié)果與另外一家公司的檢測(cè)結(jié)果進(jìn)行了對(duì)比,結(jié)果發(fā)現(xiàn)雅培的陽(yáng)性病例漏診率至少為三分之一,使用目前推薦的干鼻拭子檢測(cè),漏診率高達(dá)48%。研究人員在BioRxiv服務(wù)器上發(fā)布了這篇報(bào)告,但分析結(jié)果尚未得到證實(shí)。研究人員通常會(huì)在研究報(bào)告經(jīng)過其他科學(xué)家同行審議之前,在該服務(wù)器上發(fā)布早期成果。
雅培表示,研究人員對(duì)這種檢測(cè)裝置的使用不當(dāng),并表示公司得到的假陰性比例為0.02%。
白宮經(jīng)常使用ID NOW對(duì)工作人員、州長(zhǎng)、國(guó)會(huì)議員、記者和與總統(tǒng)密切接觸的其他人進(jìn)行檢測(cè)。這款便攜式的檢測(cè)設(shè)備只有烤面包機(jī)大小,不需要進(jìn)行深鼻腔拭子取樣。唐納德·特朗普總統(tǒng)曾經(jīng)說這種取樣方式“令人討厭”。
雅培的設(shè)備獲得在美國(guó)食品與藥品監(jiān)督管理局(Food and Drug Administration)的應(yīng)急使用授權(quán)之后,特朗普曾在白宮玫瑰花園里大肆吹捧,說它是上天賜給醫(yī)院和工作場(chǎng)所的禮物,因?yàn)樗爸灰宸昼娋湍苎杆俳o出檢測(cè)結(jié)果”。
特朗普總統(tǒng)在3月30日的發(fā)布會(huì)上稱:“現(xiàn)在局面已經(jīng)截然不同?!?/p>
紐約大學(xué)的研究結(jié)果如果能得到證實(shí),則意味著雖然雅培為了避免高假陰性率提出了一些修改建議,但其檢測(cè)結(jié)果的假陰性率依舊很高。今年4月,在其他學(xué)術(shù)研究人員發(fā)現(xiàn)問題之后,雅培告訴臨床醫(yī)生不要把樣本存放在運(yùn)送培養(yǎng)基(用于存放樣本的液體)中,以免樣本被稀釋,導(dǎo)致假陰性檢測(cè)結(jié)果。
紐約大學(xué)的研究人員考慮到這些變化,嘗試使用干拭子避免假陰性,結(jié)果卻更加糟糕。使用丹納赫集團(tuán)(Danaher Corp.)銷售的標(biāo)準(zhǔn)參照檢測(cè)系統(tǒng)Cepheid GeneXpert檢測(cè)呈陽(yáng)性的樣本,在雅培設(shè)備上檢測(cè)的漏檢率為48%。紐約大學(xué)的研究尚未經(jīng)過外部專家評(píng)審,也沒有在科學(xué)期刊上發(fā)表。
雅培表示,公司的科學(xué)家正在對(duì)這份12頁(yè)的報(bào)告進(jìn)行審議。雅培已經(jīng)分發(fā)了約180萬(wàn)套ID NOW檢測(cè)設(shè)備。該公司稱并沒有發(fā)現(xiàn)紐約大學(xué)報(bào)告中提出的問題。
雅培的發(fā)言人達(dá)爾西·羅斯說:“我們不確定樣本檢測(cè)的方法是否正確,我們正在進(jìn)一步評(píng)估他們的研究結(jié)果。如果使用設(shè)備的方法正確,檢測(cè)結(jié)果是符合預(yù)期的?!?/p>
現(xiàn)場(chǎng)檢測(cè)
雅培的ID NOW可以在醫(yī)療機(jī)構(gòu)迅速進(jìn)行即時(shí)檢測(cè)。其他檢測(cè)方法則需要將樣本運(yùn)送到實(shí)驗(yàn)室,幾天之后才能得出檢測(cè)結(jié)果。美國(guó)的病毒檢測(cè)工作嚴(yán)重滯后,這種快速檢測(cè)方法被普遍認(rèn)為是加快檢測(cè)的關(guān)鍵,可以更高效地得出檢測(cè)結(jié)果,將資源分配給真正的患者。
但假陰性問題卻讓人們質(zhì)疑,雅培的檢測(cè)是否能夠按照預(yù)期,緩解美國(guó)病毒檢測(cè)工作所面臨的壓力。
科學(xué)家們開發(fā)了多種新型冠狀病毒檢測(cè)設(shè)備,有一些設(shè)備沒有通過聯(lián)邦衛(wèi)生監(jiān)管部門的正常審查。目前仍不確定,在病毒潛伏期內(nèi)的哪個(gè)時(shí)間點(diǎn)進(jìn)行檢測(cè)最有可能得出準(zhǔn)確的結(jié)果。與病毒有關(guān)的信息依舊不足。
有一些檢測(cè)也引發(fā)了對(duì)于假陰性問題的擔(dān)憂。醫(yī)生曾報(bào)告稱有明顯新冠肺炎癥狀的患者檢測(cè)呈陰性。雖然假陰性問題的規(guī)模還無(wú)法確定,但專家認(rèn)為這個(gè)問題可能普遍存在。
假陰性會(huì)妨礙疾病診斷,導(dǎo)致無(wú)法確定疾病爆發(fā)的完整范圍,而且患者可能在不知情的情況下傳播了病毒。
美國(guó)的醫(yī)生曾報(bào)告有患者多次檢測(cè)均呈陰性,但最終檢測(cè)呈陽(yáng)性。有些醫(yī)生選擇了其他診斷方法,比如胸部X光片或CT掃描等。(財(cái)富中文網(wǎng))
譯者:Biz
美國(guó)紐約大學(xué)(New York University)的研究報(bào)告稱,白宮為快速篩查感染者所采用的雅培公司(Abbott Laboratories)的新冠病毒檢測(cè),可能漏診了近一半的陽(yáng)性病例,但雅培公司對(duì)這項(xiàng)研究結(jié)果表示質(zhì)疑。
研究人員將雅培的ID NOW檢測(cè)裝置的結(jié)果與另外一家公司的檢測(cè)結(jié)果進(jìn)行了對(duì)比,結(jié)果發(fā)現(xiàn)雅培的陽(yáng)性病例漏診率至少為三分之一,使用目前推薦的干鼻拭子檢測(cè),漏診率高達(dá)48%。研究人員在BioRxiv服務(wù)器上發(fā)布了這篇報(bào)告,但分析結(jié)果尚未得到證實(shí)。研究人員通常會(huì)在研究報(bào)告經(jīng)過其他科學(xué)家同行審議之前,在該服務(wù)器上發(fā)布早期成果。
雅培表示,研究人員對(duì)這種檢測(cè)裝置的使用不當(dāng),并表示公司得到的假陰性比例為0.02%。
白宮經(jīng)常使用ID NOW對(duì)工作人員、州長(zhǎng)、國(guó)會(huì)議員、記者和與總統(tǒng)密切接觸的其他人進(jìn)行檢測(cè)。這款便攜式的檢測(cè)設(shè)備只有烤面包機(jī)大小,不需要進(jìn)行深鼻腔拭子取樣。唐納德·特朗普總統(tǒng)曾經(jīng)說這種取樣方式“令人討厭”。
雅培的設(shè)備獲得在美國(guó)食品與藥品監(jiān)督管理局(Food and Drug Administration)的應(yīng)急使用授權(quán)之后,特朗普曾在白宮玫瑰花園里大肆吹捧,說它是上天賜給醫(yī)院和工作場(chǎng)所的禮物,因?yàn)樗爸灰宸昼娋湍苎杆俳o出檢測(cè)結(jié)果”。
特朗普總統(tǒng)在3月30日的發(fā)布會(huì)上稱:“現(xiàn)在局面已經(jīng)截然不同?!?/p>
紐約大學(xué)的研究結(jié)果如果能得到證實(shí),則意味著雖然雅培為了避免高假陰性率提出了一些修改建議,但其檢測(cè)結(jié)果的假陰性率依舊很高。今年4月,在其他學(xué)術(shù)研究人員發(fā)現(xiàn)問題之后,雅培告訴臨床醫(yī)生不要把樣本存放在運(yùn)送培養(yǎng)基(用于存放樣本的液體)中,以免樣本被稀釋,導(dǎo)致假陰性檢測(cè)結(jié)果。
紐約大學(xué)的研究人員考慮到這些變化,嘗試使用干拭子避免假陰性,結(jié)果卻更加糟糕。使用丹納赫集團(tuán)(Danaher Corp.)銷售的標(biāo)準(zhǔn)參照檢測(cè)系統(tǒng)Cepheid GeneXpert檢測(cè)呈陽(yáng)性的樣本,在雅培設(shè)備上檢測(cè)的漏檢率為48%。紐約大學(xué)的研究尚未經(jīng)過外部專家評(píng)審,也沒有在科學(xué)期刊上發(fā)表。
雅培表示,公司的科學(xué)家正在對(duì)這份12頁(yè)的報(bào)告進(jìn)行審議。雅培已經(jīng)分發(fā)了約180萬(wàn)套ID NOW檢測(cè)設(shè)備。該公司稱并沒有發(fā)現(xiàn)紐約大學(xué)報(bào)告中提出的問題。
雅培的發(fā)言人達(dá)爾西·羅斯說:“我們不確定樣本檢測(cè)的方法是否正確,我們正在進(jìn)一步評(píng)估他們的研究結(jié)果。如果使用設(shè)備的方法正確,檢測(cè)結(jié)果是符合預(yù)期的。”
現(xiàn)場(chǎng)檢測(cè)
雅培的ID NOW可以在醫(yī)療機(jī)構(gòu)迅速進(jìn)行即時(shí)檢測(cè)。其他檢測(cè)方法則需要將樣本運(yùn)送到實(shí)驗(yàn)室,幾天之后才能得出檢測(cè)結(jié)果。美國(guó)的病毒檢測(cè)工作嚴(yán)重滯后,這種快速檢測(cè)方法被普遍認(rèn)為是加快檢測(cè)的關(guān)鍵,可以更高效地得出檢測(cè)結(jié)果,將資源分配給真正的患者。
但假陰性問題卻讓人們質(zhì)疑,雅培的檢測(cè)是否能夠按照預(yù)期,緩解美國(guó)病毒檢測(cè)工作所面臨的壓力。
科學(xué)家們開發(fā)了多種新型冠狀病毒檢測(cè)設(shè)備,有一些設(shè)備沒有通過聯(lián)邦衛(wèi)生監(jiān)管部門的正常審查。目前仍不確定,在病毒潛伏期內(nèi)的哪個(gè)時(shí)間點(diǎn)進(jìn)行檢測(cè)最有可能得出準(zhǔn)確的結(jié)果。與病毒有關(guān)的信息依舊不足。
有一些檢測(cè)也引發(fā)了對(duì)于假陰性問題的擔(dān)憂。醫(yī)生曾報(bào)告稱有明顯新冠肺炎癥狀的患者檢測(cè)呈陰性。雖然假陰性問題的規(guī)模還無(wú)法確定,但專家認(rèn)為這個(gè)問題可能普遍存在。
假陰性會(huì)妨礙疾病診斷,導(dǎo)致無(wú)法確定疾病爆發(fā)的完整范圍,而且患者可能在不知情的情況下傳播了病毒。
美國(guó)的醫(yī)生曾報(bào)告有患者多次檢測(cè)均呈陰性,但最終檢測(cè)呈陽(yáng)性。有些醫(yī)生選擇了其他診斷方法,比如胸部X光片或CT掃描等。(財(cái)富中文網(wǎng))
譯者:Biz
The coronavirus test from Abbott Laboratories used at the White House to get rapid answers to whether someone is infected may miss as many as half of positive cases, according to a report from New York University that the company immediately disputed.
The analysis, which has yet to be confirmed, found that Abbott’s ID NOW missed at least one-third of positive cases detected with a rival test and as much as 48% when using the currently recommended dry nasal swabs, according to the report on BioRxiv, a server where researchers post early work before it has been reviewed by other scientists.
Abbott said the researchers didn’t use the test as intended and that the false-negative rate, as reported to the company, is 0.02%.
The White House is frequently testing staff, governors, lawmakers, reporters and others who come in close contact with the president using ID Now. The testing machine, which is roughly the size of a toaster, is portable and doesn’t require deep nasal swabs, about which President Donald Trump once said there is “nothing pleasant.”
Trump touted the Abbott machine with great fanfare in the White House Rose Garden after the Food and Drug Administration approved it for emergency use, saying it could be a godsend for hospitals and workplaces because it “delivers lightning-fast results in as little as five minutes.”
“That’s a whole new ballgame,” the president said at the March 30 event.
The results of the NYU study, if confirmed, indicate the test may still suffer from high false-negative rates despite changes recommended by the company to avoid such a problem. In April, after other academic researchers raised concerns about the issue, Abbott told clinicians to avoid storing samples in so-called transport media, a liquid used to hold the sample, as that might dilute the test and lead to false negatives.
But when the NYU authors attempted to account for changes and avoid false negatives by using dry swabs, the performance was even worse. It missed the virus in 48% of the samples that were positive using Cepheid GeneXpert, a standard reference test sold by Danaher Corp. The NYU study hasn’t yet been reviewed by outside experts or published in a scientific journal.
Abbott said its scientists are still reviewing the 12-page paper. It has distributed about 1.8 million ID NOW tests and said it hasn’t found the problem identified by the NYU report.
“It’s unclear if the samples were tested correctly, and we’re further evaluating the results,” said Darcy Ross, an Abbott spokeswoman. “The test is performing as expected when it’s used correctly.”
On-site test
Abbott’s ID NOW is a point-of-care test that can be done quickly in a health-care setting. Other tests require a sample to be shipped to a lab, with results available after several days. The rapid approach has been widely viewed as a key to ramping up hamstrung U.S. testing efforts, giving answers more efficiently and directing resources to those who are truly sick.
Concerns about false negatives, though, call into question whether the Abbott test will be able to alleviate the strain on U.S. testing efforts as intended.
Scientists have developed a variety of tests to detect the novel coronavirus,and some haven’t been vetted with the usual rigor by federal health regulators. It is also still unclear at what point in the incubation period of the virus any test is most likely to produce an accurate result. Enough information about the virus is simply not yet known.
Several tests have sparked concern about false negatives. Doctors have reported patients with obvious signs of the disease testing negative. While the scale of the problem hasn’t yet been determined, experts agree that it is prevalent.
False negatives can hinder diagnosis of disease, obscure the full scope of an outbreak and raise the potential that sick people could unknowingly spread a pathogen.
Doctors at hospitals around the country have reported patients testing negative sometimes multiple times before eventually testing positive. Some doctors have instead at times turned to other methods of diagnosis, such as chest X-rays or CT scans.